• Trial Talks Podcast
  • COVID-19
  • Blog
  • Client Login

Decentralized Trials

TargetCancer Foundation Successfully Engages and Empowers Rare Cancer Patients with Medrio

Overview TargetCancer Foundation implemented Medrio’s remote consent function in their TCF-001 TRACK study, which has an objective to determine if rare tumors can benefit from matched molecular therapy. The study is remotely enrolling a total of 400 patients in the United States using electronic informed consent. Medrio’s eClinical solution provides significant benefits to TargetCancer Foundation

The Future of RTSM: Insights and Forecasting with RTSM-Expert, Ian Davison

The Future of RTSM Home By all expert accounts, 2022 is the year that we can begin seeing the societal shift from late-stage pandemic to early-stage endemic as the world learns to live with the short- and long-term effects of COVID-19. Clinical trial operations, specifically as they relate to randomization and trial supply, have undergone one